Analysts See No Earnings Impact For Indian Suppliers As U.S. Bars Anti-Malarial Drugs For Covid-19
A magnified coronavirus germ is displayed on a desktop computer monitor at a hospital in Leuven, Belgium. (Photographer: Geert Vanden Wijngaert/Bloomberg)

Analysts See No Earnings Impact For Indian Suppliers As U.S. Bars Anti-Malarial Drugs For Covid-19

Analysts say U.S. drug regulator’s decision to revoke authorisation to use anti-malarial drugs to treat Covid-19 patients in cases of emergency will impact Indian pharma companies in the short term...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.